The UK's drug laws are preventing scientists from carrying out vital research to unlock our understanding of the brain and find new treatments for conditions such as depression and Parkinson's disease, according to Professor David Nutt, a leading neuroscientist and former government drug adviser. "Things are actually getting worse," said Nutt, referring to the restrictions placed on research.
As Americans continue to embrace pot—as medicine and for recreational use—opponents are turning to a set of academic researchers to claim that policymakers should avoid relaxing restrictions around marijuana. It's too dangerous, risky, and untested, they say. Just as drug company-funded research has become incredibly controversial in recent years, forcing major medical schools and journals to institute strict disclosure requirements, could there be a conflict of interest issue in the pot debate? (See also: The real reason pot is still illegal)
A pro-marijuana group lost its legal battle when a federal appellate court ruled that marijuana would remain a Schedule I drug, defined as having no accepted medical value and a high potential for abuse. For years, the U.S. Drug Enforcement Administration and the National Institute for Drug Abuse have made it all but impossible to develop a robust body of research on the medical uses of marijuana. For a muscular agency that combats vicious drug criminals, the DEA acts like a terrified and obstinate toddler when it comes to basic science.